Prognostic factors in localized invasive primary cutaneous malignant melanoma: Results of a large population-based study

British Journal of Dermatology

Volumn 172, Issue 1, 2015, Pages 175-186

  Eriksson, H ^a   Frohm Nilsson, M ^a   Jaras J ^b   Kanter Lewensohn, L ^a   Kjellman, P ^a   Mansson Brahme E ^a   Vassilaki, I ^a   Hansson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; GROWTH CURVE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MALIGNANT NEOPLASTIC DISEASE; MITOSIS RATE; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION; AGE DISTRIBUTION; CLINICAL TRIAL; EPIDEMIOLOGY; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; ONSET AGE; PATHOLOGY; PROGNOSIS; SEX RATIO; SKIN TUMOR; SWEDEN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE OF ONSET; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SEX DISTRIBUTION; SKIN NEOPLASMS; SWEDEN; YOUNG ADULT;

EID: 84920720011     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13171     Document Type: Article

References (31)

1. Balch CM, Soong SJ, Gershenwald JE, et al,. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
2. Balch CM, Buzaid AC, Soong SJ, et al,. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
3. Thorn M, Ponten F, Bergstrom R, et al,. Clinical and histopathologic predictors of survival in patients with malignant melanoma: a population-based study in Sweden. J Natl Cancer Inst 1994; 86: 761-9.
4. Lindholm C, Andersson R, Dufmats M, et al,. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer 2004; 101: 2067-78.
5. Azimi F, Scolyer RA, Rumcheva P, et al,. Tumour-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30: 2678-83.
6. Lyth J, Hansson J, Ingvar C, et al,. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. Br J Dermatol 2013; 168: 779-86.
7. Balch CM, Gershenwald JE, Soong SJ, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
8. Masback A, Olsson H, Westerdahl J, et al,. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11: 435-45.
9. Clemente CG, Mihm MG, Bufalino R, et al,. Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
10. Clark WH, Elder DE, Guerry D, et al,. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893-904.
11. Ronan SG, Eng AM, Briele HA, et al,. Thin malignant melanomas with regression and metastases. Arch Dermatol 1987; 123: 1326-30.
12. McGovern VJ, Shaw HM, Milton GW,. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology 1983; 7: 673-80.
13. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al,. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-67.
14. Eriksson H, Frohm-Nilsson M, Hedblad MA, et al,. Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management. Acta Derm Venereol 2013; 93: 411-16.
15. Scolyer RA, Shaw HM, Thompson JF, et al,. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 2003; 27: 1571-6.
16. Thomas NE, Busam KJ, From L, et al,. Tumour-infiltrating lymphocyte grade in primary melanomas is independently associa-ted with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 2013; 31: 4252-9.
17. McShane LM, Altman DG, Sauerbrei W, et al,. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-91.
18. Thompson JF, Soong S-J, Balch CM, et al,. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29: 2199-205.
19. Azzola MF, Shaw HM, Thompson JF, et al,. Tumour mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-98.
20. Francken AB, Shaw HM, Thompson JF, et al,. The prognostic importance of tumour mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426-33.
21. Barnhill RL, Katzen J, Spatz A, et al,. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005; 32: 268-73.
22. Gimotty PA, Guerry D, Ming ME, et al,. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 2004; 22: 3668-76.
23. Larsen TE, Little JH, Orell SR, et al,. International pathologists congruence survey on quantitation of malignant melanoma. Pathology 1980; 12: 245-53.
24. Heenan PJ, Matz LR, Blackwell JB, et al,. Inter-observer variation between pathologists in the classification of cutaneous malignant melanoma in western Australia. Histopathology 1984; 8: 717-29.
25. Lasithiotakis K, Leiter U, Meier F, et al,. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112: 1795-804.
26. Gimotty PA, Botbyl J, Soong SJ, et al,. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2005; 23: 8065-75.
27. Thorn M, Ponten F, Bergstrom R, et al,. Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. Br J Cancer 1994; 70: 743-8.
28. Barnhill RL, Fine JA, Roush GC, et al,. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78: 427-32.
29. Averbook BJ,. Mitotic rate and sentinel lymph node tumour burden topography: integration into melanoma staging and stratification use in clinical trials. J Clin Oncol 2011; 29: 2137-41.
30. Gimotty PA, Elder DE, Fraker DL, et al,. Identification of High-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007; 25: 1129-34.
31. Breslow A,. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.